EFPIA says Europe still divided on medicines access

New figures from European industry group EFPIA paint a stark picture of the growing divide in access to innovative medicines across the EU, with patients in some countries waiting more than seven times longer than others for the same treatment.
According to the latest Patients W.A.I.T. Indicator, just 46% of new medicines approved by the European Medicines Agency between 2020 and 2023 were available to patients through national systems. Public reimbursement was even rarer, covering only 29% of those products — down from 42% in 2019.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source